About UCB, Inc.
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).
217 articles with UCB, Inc.
Sanofi, UCB, McKesson Ventures, and Horizon Health Services Endorse Aetion's Vision for Real-World Evidence
This follows a 2017 rejection by the agency, requesting more data. As Jefferies analyst Michael Yee wrote in a note to clients, Amgen is “back in the game.”
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen and UCB today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.
Patient-centric drug delivery important for treatment adherence, commercial success
- Revenue reached € 3.4 billion (+3%; +6% CER)
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
UCB, a global biopharmaceutical company, presented long-term data for the first time from BE ACTIVE, showing that response rates across musculoskeletal and skin manifestations with bimekizumab continued to increase in the dose-blind study period after Week 12, through Week 24, and were sustained to Week 48 in psoriatic arthritis (PsA) patients.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis
Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA® (certolizumab pegol) in this patient population when added to common background medications
Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints
On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored
Survey finds 7 in 10 women ages 60+ think fragile bones are an inevitable part of getting older while underlying osteoporosis may be the cause
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational produc...
8/13/2018Midazolam Nasal Spray has also been granted Fast Track designation by the US FDA due to the high unmet need for patients and caregivers
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients
Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.
New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
Survey reveals that women of childbearing age with chronic rheumatic diseases experience unique challenges, and suggests many experience a lack of guidance and consistent information regarding family planning and treatment during their pregnancy journey and breastfeeding
Quebecers Living with Advanced Parkinson's Disease Now Have Broader Access to NEUPRO (rotigotine) As Add-On Therapy
UCB Canada Inc. announced today that Quebecers now have publicly funded access (special authorization) to NEUPRO® (rotigotine) for the treatment of advanced stage Parkinson's Disease (APD), in combination with the drug levodopa.
Canadians Living with Advanced Parkinson's Disease Now Have Broader Access to NEUPRO (rotigotine) As Add-On Therapy
UCB Canada Inc. announced that NEUPRO® (rotigotine) is now available through public funding (special authorization) all across Canada*, in combination with the drug levodopa for the treatment of patients with advanced stage Parkinson's Disease (APD).
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA® (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
UCB today announced positive topline results from C-AXSPAND, a Phase 3 placebo controlled study to investigate the efficacy of CIMZIA® (certolizumab pegol) on the signs and symptoms of active axSpA in patients without x-ray evidence of ankylosing spondylitis (AS).